- Canadian drugmaker Valeant Pharmaceuticals (NYSE:VRX) has offered to purchase the entirety of Medicis Pharmaceuticals (NYSE:MRX) this morning for $2.6B, or $44 per share. On August … Continue Reading
Read nowLong Ideas - Sources at Roche (OTCQX: RHHBY) told PropThink on Wednesday that products being jointly developed with Halozyme Therapeutics (NASDAQ: HALO) will not face issues seen with … Continue Reading
Read now- Onyx Pharmaceuticals (NASDAQ:ONXX) just announced FDA approval of Kyprolis (carfilzomib), ONXX’s next-generation treatment for multiple myeloma. The FDA action (PDUFA) date was set for July … Continue Reading
Read nowLong Ideas - Among the next significant events in pharma and biotech is the FDA decision on Kyprolis (carfilzomib), Onyx Pharmaceuticals’ (NASDAQ:ONXX)next-generation treatment for multiple myeloma. On July … Continue Reading
Read now- Vivus (NASDAQ:VVUS) announced FDA approval of its anti-obesity drug, Qsymia, last night and importantly, physicians can prescribe the medicine to patients without major restrictions. The … Continue Reading
Read now